Eli Lilly and Company (LLY) Income Statement
LLY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLLY revenue and net income
Where LLY's revenue goes
2025Each bar shows an amount and its share of revenue. LLY kept 31.7% of revenue as net income.
LLY profit margins
LLY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +44.7% | +31.7% | +21.6% | +12.6% |
| Gross profit | +47.8% | +35.2% | +23.2% | +13.8% |
| Operating income | +74.3% | +50.8% | +32.7% | +23.5% |
| Net income | +94.9% | +49.0% | +27.2% | +24.0% |
| EPS (diluted) | +86.2% | +45.0% | +25.0% | +21.5% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LLY quarterly EPS vs estimates
Eli Lilly beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: October 29, 2026 (estimate $5.38).
LLY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B | $24.54B | $22.32B | $21.49B | $19.97B | $21.22B |
| Cost of revenue | $11.05B | $8.42B | $7.08B | $6.63B | $7.31B | $5.48B | $4.72B | $4.68B | $4.45B | $5.71B |
| Gross profit | $54.13B | $36.62B | $27.04B | $21.91B | $21.01B | $19.06B | $17.60B | $16.81B | $15.53B | $15.51B |
| Research & development | $13.34B | $10.99B | $9.31B | $7.19B | $6.93B | $5.98B | $5.59B | $5.05B | $5.10B | $5.31B |
| Sales, general & admin | $11.09B | $8.59B | $6.94B | $6.07B | $6.14B | $5.87B | $6.00B | $5.73B | $6.18B | $6.33B |
| Total operating expenses | $24.43B | $19.59B | $16.25B | $13.26B | $13.07B | $11.85B | $11.60B | $10.79B | $11.28B | $11.64B |
| Operating income | $29.70B | $17.04B | $10.79B | $8.65B | $7.93B | $7.21B | $6.00B | $6.03B | $4.25B | $3.87B |
| Interest income | $642.0M | $175.2M | $173.6M | $268.8M | $314.4M | $326.6M | $80.4M | $161.3M | $167.3M | $108.7M |
| Interest expense | $795.3M | $780.6M | $485.9M | $331.6M | $339.8M | $359.6M | $400.6M | $242.5M | $225.0M | $185.2M |
| Income before taxes | $25.73B | $12.68B | $6.55B | $6.81B | $6.16B | $7.23B | $5.27B | $3.68B | $2.30B | $3.37B |
| Income taxes | $5.09B | $2.09B | $1.31B | $561.6M | $573.8M | $1.04B | $628.0M | $529.5M | $2.39B | $636.4M |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B | $6.19B | $8.32B | $3.23B | −$204.1M | $2.74B |
| EBITDA | $31.69B | $18.81B | $8.57B | $8.66B | $8.04B | $8.91B | $6.90B | $5.53B | $4.10B | $5.06B |
| EPS (diluted) | $24.21 | $13.00 | $6.32 | $7.94 | $8.17 | $7.93 | $6.04 | $5.56 | $4.28 | $3.52 |
| Gross margin | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% |
| Operating margin | 45.6% | 37.8% | 31.6% | 30.3% | 28.0% | 29.4% | 26.9% | 28.0% | 21.3% | 18.2% |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | −1.0% | 12.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.97B | $19.80B | $19.29B | $17.60B | $15.56B | $12.73B | $13.53B | $11.44B | $11.30B | $8.77B | $9.35B | $9.50B |
| Cost of revenue | $3.27B | $3.58B | $3.37B | $3.01B | $2.45B | $2.23B | $2.40B | $2.17B | $2.17B | $1.67B | $1.79B | $1.86B |
| Gross profit | $19.71B | $16.22B | $15.92B | $14.59B | $13.11B | $10.50B | $11.13B | $9.27B | $9.13B | $7.09B | $7.57B | $7.64B |
| Research & development | $3.82B | $3.51B | $3.80B | $3.47B | $3.34B | $2.73B | $3.02B | $2.73B | $2.71B | $2.52B | $2.56B | $2.41B |
| Sales, general & admin | $3.43B | $2.93B | $3.34B | $2.74B | $2.75B | $2.47B | $2.42B | $2.10B | $2.00B | $1.84B | $1.81B | $1.69B |
| Total operating expenses | $7.25B | $6.44B | $6.93B | $6.21B | $6.09B | $5.20B | $5.45B | $4.83B | $4.71B | $4.36B | $4.37B | $4.10B |
| Operating income | $12.46B | $9.78B | $8.99B | $8.39B | $7.02B | $5.30B | $5.68B | $4.43B | $4.42B | $2.74B | $3.19B | $3.54B |
| Interest income | — | — | $123.0M | $65.0M | $40.0M | $48.3M | $44.3M | $47.8M | $37.3M | $45.8M | $44.5M | $138.6M |
| Interest expense | $345.0M | $332.0M | $123.0M | $179.6M | $249.0M | $243.7M | $224.7M | $192.7M | $183.6M | $179.6M | $138.2M | $124.6M |
| Income before taxes | $9.25B | $8.85B | $8.27B | $7.23B | $6.78B | $3.46B | $5.04B | $1.59B | $3.52B | $2.54B | $2.51B | $427.2M |
| Income taxes | $2.15B | $1.45B | $1.63B | $1.65B | $1.12B | $697.0M | $628.9M | $618.1M | $550.2M | $293.2M | $319.1M | $484.6M |
| Net income | $7.09B | $7.40B | $6.64B | $5.58B | $5.66B | $2.76B | $4.41B | $970.3M | $2.97B | $2.24B | $2.19B | −$57.4M |
| EBITDA | $12.99B | $10.29B | $12.14B | $7.88B | $7.50B | $5.76B | $5.75B | $2.25B | $4.12B | $3.12B | $3.03B | $962.8M |
| EPS (diluted) | $8.38 | $8.55 | $7.54 | $7.02 | $6.31 | $3.34 | $5.32 | $1.18 | $3.92 | $2.58 | $2.49 | $0.10 |
| Gross margin | 85.8% | 81.9% | 82.5% | 82.9% | 84.3% | 82.5% | 82.2% | 81.0% | 80.8% | 80.9% | 80.9% | 80.4% |
| Operating margin | 54.2% | 49.4% | 46.6% | 47.6% | 45.1% | 41.7% | 42.0% | 38.8% | 39.1% | 31.2% | 34.1% | 37.3% |
| Net margin | 30.9% | 37.4% | 34.4% | 31.7% | 36.4% | 21.7% | 32.6% | 8.5% | 26.3% | 25.6% | 23.4% | −0.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LLY's financial statements (latest annual report filed February 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LLY financial results
In fiscal year 2025 (ended December 31, 2025), Eli Lilly reported revenue of $65.2 billion, up 44.7% from the year before. It had net income of $20.6 billion (up 94.9%), a net profit margin of 31.7%. Diluted earnings per share came to $24.21. Over five years revenue grew at an average rate of 21.6% a year.
See the LLY stock overview for the latest quote and news, or the LLY chart for price history and technical indicators.
LLY income statement FAQ
What is Eli Lilly's annual revenue?
Eli Lilly reported total revenue of $65.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 44.7% from $45.0 billion the previous year.
Is Eli Lilly profitable?
Yes. Eli Lilly reported net income of $20.6 billion in fiscal 2025, a net profit margin of 31.7%; its operating margin was 45.6%.
What is Eli Lilly's gross margin?
Eli Lilly's gross margin was 83.0% in fiscal 2025: for every $100 of revenue, Eli Lilly kept $83 after the direct cost of its products and services.
How much does Eli Lilly spend on research and development?
Eli Lilly spent $13.3 billion on research and development in fiscal 2025, 20.5% of revenue.
How fast is Eli Lilly growing?
Revenue grew 21.6% a year on average over the last five fiscal years, from $24.5 billion to $65.2 billion.
What are Eli Lilly's earnings per share?
Eli Lilly earned $24.21 per diluted share in fiscal 2025, compared with $13.00 a year earlier.
When will Eli Lilly report its next earnings?
Eli Lilly is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens.
When does Eli Lilly's fiscal year end?
Eli Lilly's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 12, 2026.